Antithrombotic Safety Linked to GFR
Fondaparinux may be safer than enoxaparin as treatment for non-ST-segment elevation acute coronary syndromes (ACS) in patients with renal dysfunction.
Diagnosis & Disease Information
More Type 2 Diabetics Face ESRD
End-stage renal disease (ESRD) is affecting a growing proportion of type 2 diabetics in Australia and New Zealand, a study found.
Lowering Homocysteine Not Beneficial
Using high doses of folic acid and B vitamins to lower elevated homocysteine levels in patients with advanced CKD (ACKD) or end-stage renal disease (ESRD) does not improve survival or decrease the incidence of vascular disease, data show.
How to Manage Vitamin D Deficiency
The active forms of vitamin D—calcitriol, paricalcitol, and doxercalciferol—which also are known as vitamin D receptor activators (VDRAs), have been largely used in nephrology only as a treatment for secondary hyperparathyroidism, an elevation in parathyroid hormone (PTH) due to renal failure.
Untreated Anemia Increases Morbidity
CHICAGO—Diabetics with CKD whose anemia is untreated have twice the overall risk of CVD-related hospitalizations, according to data reported at the 67th Scientific Sessions of the American Diabetes Association.
Uric Acid Tied to CKD Progression
Higher levels of uric acid are weakly but significantly associated with progression of kidney disease, according to researchers.
Pentraxin 3 Elevated in HD Patients
Pentraxin 3, a mediator of inflammation, is markedly elevated in patients on hemodialysis (HD) but not in patients on peritoneal dialysis (PD) or in patients with chronic renal failure (CRF) not on dialysis, according to researchers.
Membranous Nephropathy Hikes Cancer Risk
Patients with membranous nephropathy (MN) are at increased risk of developing cancer, according to researchers in Norway.
Obesity, Hyperparathyroidism Linked in CKD
Elevated BMI is associated with secondary hyperparathyroidism in non-dialysis CKD patients, especially patients who have evidence of malnutrition and inflammation, a study found.
Extended Epoetin Alfa Dosing Effects Similar in Diabetics
Patients with and without diabetes respond similarly to extended dosing of epoetin alfa as infrequently as once every four weeks, data show.
- Loading...
Loading...
Loading... 
Loading...